NASDAQ$LXRX
Lexicon Pharmaceuticals Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for Q1 2021 and provided a clinical update.
Lexicon Pharmaceuticals reported negligible revenues for the first quarter of 2021, primarily due to the absence of product revenues following the sale of XERMELO in Q3 2020. Net loss for the quarter was $21.0 million, or $0.15 per share, compared to a net loss of $66.6 million, or $0.63 per share, for the corresponding period in 2020. The company had $141.4 million in cash and investments as of March 31, 2021.
- Patient enrollment continued in Phase 2 clinical studies for LX9211 in neuropathic pain, with results expected by the end of the year.
- FDA provided regulatory feedback on sotagliflozin in heart failure, and the company is moving forward with a planned NDA filing this year.
- Revenues for the first quarter were negligible compared to $8.0 million in the corresponding period in 2020 due to the sale of XERMELO.
- Research and development expenses decreased to $12.6 million from $55.2 million for the corresponding period in 2020, primarily due to decreases in external clinical development costs related to sotagliflozin.
Headline financials
Revenue & EPS history
Lexicon Pharmaceuticals · Revenue · Quarterly
$27K
Revenue by segment
Lexicon Pharmaceuticals · $162K total across 2 segments · Q3 2023
- Net Product Revenue$148K—91.4%
- Royalties and Other$14K—8.6%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+0.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
-0.4%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+30.6%
Q3 2015
Best reaction
-26.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.4% | +50.0% | +19.4% | |
| Q4 2025 | -0.6% | +1.8% | -2.5% | |
| Q3 2025 | +3.0% | +13.0% | +1.4% | |
| Q1 2025 | +3.1% | +22.2% | +24.1% | |
| Q4 2024 | +6.6% | +2.7% | +13.5% | |
| Q3 2024 | -14.2% | -22.8% | -35.4% | |
| Q2 2024 | -24.4% | -27.1% | -23.1% | |
| Q1 2024 | +5.5% | +7.3% | +3.0% | |
| Q4 2023 | +16.1% | +19.8% | -6.9% | |
| Q3 2023 | -17.2% | -14.4% | +0.0% | |
| Q2 2023 | -1.1% | -3.7% | -10.6% | |
| Q1 2023 | +12.3% | +43.0% | +11.1% | |
| Q4 2022 | +21.8% | +17.3% | +10.5% | |
| Q3 2022 | +8.7% | +13.1% | -1.0% | |
| Q2 2022 | +13.5% | +19.4% | +16.5% | |
| Q1 2022 | -7.2% | -9.8% | -6.7% | |
| Q4 2021 | -26.0% | -25.3% | -26.3% | |
| Q3 2021 | -11.2% | -9.8% | -25.5% | |
| Q2 2021 | +2.0% | -4.7% | +28.8% | |
| Q1 2021 | -0.4% | -3.7% | -3.5% | |
| Q4 2020 | -1.4% | -2.6% | -23.8% | |
| Q3 2020 | -9.0% | -9.8% | +32.8% | |
| Q2 2020 | +11.5% | +12.6% | +0.0% | |
| Q1 2020 | +3.4% | -7.3% | -1.0% | |
| Q4 2019 | -10.6% | +3.5% | -17.2% | |
| Q3 2019 | -8.6% | -8.8% | +26.5% | |
| Q2 2019 | -21.1% | -19.9% | -20.5% | |
| Q1 2019 | +4.7% | +20.9% | -7.2% | |
| Q4 2018 | +2.2% | +6.3% | -15.3% | |
| Q3 2018 | +8.4% | +8.8% | +3.4% | |
| Q2 2018 | -3.0% | -11.8% | -6.2% | |
| Q1 2018 | +8.4% | +17.3% | +52.2% | |
| Q4 2017 | +1.3% | +4.5% | -1.3% | |
| Q3 2017 | -6.3% | +0.8% | +8.4% | |
| Q2 2017 | -4.4% | -3.7% | -7.1% | |
| Q1 2017 | +2.4% | +2.2% | -9.5% | |
| Q4 2016 | +9.0% | +11.0% | -4.8% | |
| Q3 2016 | -4.2% | -3.0% | -1.3% | |
| Q2 2016 | +1.6% | +0.6% | -11.8% | |
| Q1 2016 | -15.6% | — | — | |
| Q4 2015 | +24.4% | — | — | |
| Q3 2015 | +30.6% | — | — | |
| Q2 2015 | -8.6% | — | — | |
| Q1 2015 | -5.7% | — | — | |
| Q4 2014 | +14.3% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | -6.6% | — | — | |
| Q1 2014 | +1.4% | — | — | |
| Q4 2013 | +3.8% | — | — | |
| Q3 2013 | -2.6% | — | — | |
| Q2 2013 | +7.8% | — | — | |
| Q1 2013 | +2.5% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | -9.6% | — | — | |
| Q2 2012 | +3.7% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q4 2011 | +5.6% | — | — | |
| Q3 2011 | -9.9% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +1.9% | — | — | |
| Q4 2010 | +6.3% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +8.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro